Stereotactic ablative radiotherapy for small lung tumors with a moderate dose

摘要: Stereotactic ablative body radiotherapy (SBRT, SABR) is being increasingly applied because of its high local efficacy, e.g., for small lung tumors. However, the optimum dosage still under discussion. Here, we report data on 45 lesions [non-small cell cancer (NSCLC) or metastases] in 39 patients treated between 2009 and 2010 by SABR. SABR was performed with total doses 35 Gy (5 fractions) 37.5 Gy (3 prescribed to 60% isodose line encompassing planning target volume. Three-monthly follow-up CT scans were supplemented FDG-PET/CT if clinically indicated. The median 17 months. Local progression-free survival rates 90.5% (all patients), 95.0% (NSCLC), 81.8% (metastases) at 1 year. At 2 years, respective 80.5%, 95.0%, 59.7%. Overall 71.1% 65.4% 83.3% 2 years 52.7%, 45.9%, 66.7%, respectively. Acute side effects mild. With moderate dose schedule used, well-tolerated led favorable tumor control as other published series. Standardization reporting prescription needed allow comparison different series order determine dosage.